Advanced Search

Journal Navigation

Journal Home



Contact Us

Table of Contents

Click here to register today!

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nyberg, S. L.
Right arrow Articles by Rosen, C. B.
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Graft, Vol. 5, No. 7, 374-382 (2002)
DOI: 10.1177/152216202237621
© 2002 SAGE Publications

The Role of Cell-Based Bioartificial Liver Therapy in the Treatment of Fulminant Hepatic Failure

Scott L. Nyberg

Takakazu Matsushita

Gregory J. Gores

J. Eileen Hay

Russell H. Wiesner

Alvaro A. Pineda

Dennis A. Gastineau

S. Breanndan Moore

David J. Plevak

Eelco F. Wijdicks

David G. Piepgras

Jeffrey L. Platt

Charles B. Rosen

Fulminant liver failure (FHF) is associated with a high rate of mortality. Cell-based liversupport systems have been developed for the treatment of FHF to prevent the developmentof potentially life-ending complications such as cerebral edema, intracranial hypertension,and brain herniation. Extracorporeal liver support systems, such as the bio-artificialliver (BAL), contain hepatocytes intended to provide auxiliary hepatic functionas a bridge to liver transplantation. Clinical trials indicate that the beneficial effects ofBAL therapy include a reduction of cerebral edema and intracranial pressure, along withthe possibility of spontaneous recovery in some cases. Enhancements to the BAL suchas increasing the mass of viable and metabolically active hepatocytes are likely to beassociated with greater efficacy in future clinical trials.

Key Words: fulminant hepatic failure • bioartificial liver • intracranial pressure • systemic inflammatory response syndrome

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?